Our overall results provide novel insights on the role of SET in KMT2A-R leukemia, via modulation of HOXA gene expression and MYC stability, and a proof of concept that inhibition of SET is a promising novel strategy to treat this aggressive form of acute leukemia. Here, SET is linked to acute leukemia.